Whether to use ATP is not clear-cut and the choice should be made through shared decision-making, one expert says.

Cellular immunotherapies for cancer are associated with a low rate of serious adverse cardiac events in patients with ...

A study reinforces the importance of supporting the arm and placing the BP cuff at heart level, as guidelines recommend.

The incidental mammogram finding isn’t a reason to panic, but it might a reason to make sure other risk factors are under ...

Guideline recommendations for acute pulmonary embolism (PE) developed by prominent professional societies give a mixed bag of advice across the US and Europe, according to a paper published online ...

With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert ...

The randomized study lasted just 3 months, but researchers saw “multiple cardiometabolic benefits” beyond weight loss.

Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

In one study, outcomes were similar regardless of baseline LVEF and recent worsening HF emerged as an important indicator.

Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.

Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.